Nanoviricides, Inc. (NNVC) Stock Price & Analysis
Nanoviricides, Inc. (NNVC) fell 2.10% to USD 1.4 as of June 10, 2026 at 04:58 UTC, according to Nexqual real-time market data.
NNVC last closed at USD 1.43; the session ranged USD 1.35–1.49 on volume of 278,193 shares. Market capitalization is $32.18M, with a 52-week range of USD 0.85–2.23 (ASE). Source: Nexqual, June 10, 2026 at 04:58 UTC.
Key Statistics (as of June 10, 2026 at 04:58 UTC)
| Price | USD 1.4 |
|---|---|
| Change | ▼ 2.10% (down) |
| Previous Close | USD 1.43 |
| Open | USD 1.42 |
| Day Range | USD 1.35 – 1.49 |
| 52-Week Range | USD 0.85 – 2.23 |
| Volume | 278,193 shares |
| Market Cap | $32.18M |
| Exchange | ASE |
Technical Analysis (NNVC)
Nexqual's technical model rates NNVC "BUY" based on 4 bullish and 2 bearish signals across 123 daily candles, as of June 10, 2026 at 04:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.43 (neutral) |
| vs SMA50 | Above (USD 1.35) |
| MACD | 0.03 (positive) |
Analyst Ratings (NNVC)
Wall Street analysts rate NNVC "Strong Buy" based on 1 analysts, with a mean price target of USD 6 (range USD 6–6), per Nexqual as of June 10, 2026 at 04:58 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 6 |
| High Target | USD 6 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NNVC)
| EPS Estimate | USD -0.09 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.09 vs est -0.08 ▼ miss |
| 2025-12-31 | USD -0.11 vs est -0.08 ▼ miss |
| 2025-09-30 | USD -0.1 vs est -0.18 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:58 UTC.
Financials & Fundamentals (NNVC)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -89.97% |
| Current Ratio | 3.17 |
| Total Cash | $3.21M |
| Total Debt | $0 |
| Free Cash Flow | $-4.39M |
Source: Nexqual, June 10, 2026 at 04:58 UTC.
Financial Health Score (NNVC)
Nexqual rates Nanoviricides, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:58 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $3M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Critical — ROE -90%, ROA -50.5% |
Ownership (NNVC)
| Insider Ownership | +2.64% |
|---|---|
| Institutional Ownership | +8.34% |
| Shares Outstanding | 22.98M |
| Float | 21.08M |
| Short % of Float | +7.46% |
Source: Nexqual, June 10, 2026 at 04:58 UTC.
Leadership (NNVC)
Nanoviricides, Inc. is led by Anil R. Diwan (age 66), Executive Chairman, President, CEO & Secretary, per Nexqual as of June 10, 2026 at 04:58 UTC.
| Executive Chairman, President, CEO & Secretary | Anil R. Diwan (age 66) |
|---|---|
| CFO & Compliance Officer | Meeta R. Vyas B.S., M.B.A., SB (age 66) |
Major Backers & Investors (NNVC)
Notable institutional backers of Nanoviricides, Inc. include UBS Group AG, Fidelity, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 04:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 0.93% |
| Fidelity | 0.78% |
| Renaissance Technologies | 0.59% |
| Miller Financial Services LLC | 0.46% |
| Susquehanna International Group, LLP | 0.43% |
| Squarepoint Ops LLC | 0.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.85% |
| Geode Capital | 0.98% |
| BlackRock | 0.69% |
| State Street | 0.24% |
Source: Nexqual, June 10, 2026 at 04:58 UTC.
From Nanoviricides, Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)
Key Strengths & Strategy (as disclosed to the SEC)
- NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections.
- It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia.
- In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | USD 4.5 | ▼ 20.07% |
| APT | Alpha Pro Tech, Ltd. | USD 5.37 | ▲ 4.68% |
| AEMD | Aethlon Medical, Inc. | USD 1.94 | ▲ 1.57% |
| AIM | AIM ImmunoTech Inc. | USD 0.4 | ▼ 22.5% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:58 UTC. This page is informational and not investment advice.